Indication
Kaposi's sarcoma
Kaposi's sarcoma is a low-grade vascular neoplastic disorder caused by infection with human herpesvirus 8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus. Read more about Kaposi's sarcoma
41 drugs 33 manufacturers
Drugs that treat it
Common Kaposi's sarcoma therapies.
PACLITAXEL
POMALIDOMIDE
POMALIDOMIDE
POMALIDOMIDE
POMALIDOMIDE
POMALIDOMIDE
PACLITAXEL
PACLITAXEL
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonKaposi's sarcoma is a low-grade vascular neoplastic disorder caused by infection with human herpesvirus 8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus.
It primarily affects individuals with compromised immune systems—notably people living with advanced HIV infection (AIDS-defining illness) and solid-organ transplant recipients—as well as distinct demographic groups presenting with classic (older Mediterranean or Eastern European men) or endemic (equatorial African) forms.
Pathophysiologically, the tumor arises from lymphatic endothelial-lineage cells, leading to multifocal vascular proliferation, spindle-cell infiltration, and extravasated erythrocytes.
Clinically, it manifests as nonpruritic, violaceous, brownish, or reddish macules, plaques, and nodules that commonly involve the skin, oral mucosa, and lymph nodes, with potential dissemination to the gastrointestinal and respiratory tracts causing mucosal bleeding or airway compromise.
- cancer.org
Kaposi's sarcoma is a low-grade vascular neoplastic disorder caused by infection with human herpesvirus 8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus Pathophysiologically, the tumor arises from lymphatic endothelial-lineage cells, leading to multifocal vascular proliferation, spindle-cell infiltration, and extravasated erythrocytes Clinically, it manifests as nonpruritic, violaceous, brownish, or reddish macules, plaques, and nodules that commonly involve the skin, oral mucosa, ...
- cancer.gov
It primarily affects individuals with compromised immune systems—notably people living with advanced HIV infection (AIDS-defining illness) and solid-organ transplant recipients—as well as distinct demographic groups presenting with classic (older Mediterranean or Eastern European men) or endemic (equatorial African) forms
- hiv.gov
It primarily affects individuals with compromised immune systems—notably people living with advanced HIV infection (AIDS-defining illness) and solid-organ transplant recipients—as well as distinct demographic groups presenting with classic (older Mediterranean or Eastern European men) or endemic (equatorial African) forms
- medlineplus.gov
It primarily affects individuals with compromised immune systems—notably people living with advanced HIV infection (AIDS-defining illness) and solid-organ transplant recipients—as well as distinct demographic groups presenting with classic (older Mediterranean or Eastern European men) or endemic (equatorial African) forms Pathophysiologically, the tumor arises from lymphatic endothelial-lineage cells, leading to multifocal vascular proliferation, spindle-cell infiltration, and extravasated eryth...
- nih.gov
Clinically, it manifests as nonpruritic, violaceous, brownish, or reddish macules, plaques, and nodules that commonly involve the skin, oral mucosa, and lymph nodes, with potential dissemination to the gastrointestinal and respiratory tracts causing mucosal bleeding or airway compromise
Personalize your experience
Follow Kaposi's sarcoma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.